AMLX

Amylyx Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website amylyx.com
Employees(FY) 374
ISIN US03237H1014

Performance

-8.16%

-22.41%

+40.62%

+150.0%

-72.49%

YTD

-70.67%

Profile

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of AMLX 2024-12-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 30, Oscillators Score at 43, and a Technical Score of 36, suggesting overall weakness in price momentum and a lack of bullish signals in the market. This combination indicates that caution is warranted for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AMLX

Stock Rank

Recent News & Updates

2024-12-04 18:35
Amylyx announces design of LUCIDITY clinical trial(Yahoo Finance)
2024-12-03 18:30
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia(Businesswire)
2024-11-26 20:00
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference(Businesswire)
2024-11-07 13:11
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...(Yahoo Finance)
2024-11-07 12:33
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call(Yahoo Finance)
2024-11-06 18:00
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results(Businesswire)
2024-11-03 20:00
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024(Businesswire)
2024-10-25 09:05
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc(Yahoo Finance)
2024-10-18 23:12
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments(Yahoo Finance)
2024-10-17 19:34
Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial(Yahoo Finance)
2024-10-17 19:26
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week(Yahoo Finance)
2024-10-17 19:04
PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug(Yahoo Finance)
2024-10-16 21:00
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome(Businesswire)
2024-10-14 21:00
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024(Businesswire)
2024-10-09 05:32
Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ...(Yahoo Finance)
2024-09-09 07:17
Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)(Yahoo Finance)
2024-09-05 13:49
Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)(Yahoo Finance)
2024-08-27 20:30
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences(Businesswire)
2024-08-11 21:00
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration(Businesswire)
2024-08-07 19:00
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results(Businesswire)
2024-08-04 21:00
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024(Businesswire)
2024-08-04 16:32
EC grants orphan drug status for Amylyxs Wolfram treatment(Yahoo Finance)
2024-08-01 21:00
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome(Businesswire)
2024-07-09 22:53
Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition(Yahoo Finance)
2024-07-09 19:00
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation(Businesswire)
2024-07-09 15:00
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs(Yahoo Finance)
2024-07-09 04:01
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide(Businesswire)
2024-06-27 23:02
Amylyx ventures into metabolic diseases market with $35.1m deal(Yahoo Finance)
2024-06-03 21:00
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference(Businesswire)
2024-05-13 19:25
Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating(Yahoo Finance)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.